JAC Advance Access published online on November 16, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh485
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Laboratory of Experimental Infection, Infectious Disease Service;, Hospital de Bellvitge, University of Barcelona, C/Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
* To whom correspondence should be addressed. Objectives: Successful therapy of carbapenem-resistant Acinetobacter baumannii strains has been reported with colistin, but recently we argued against its use as monotherapy because of the poor results obtained in a mouse pneumonia model. Our aim was to identify antibiotic combinations that were valid therapeutic alternatives in the same model. Methods: We used two carbapenem-resistant A. baumannii strains (D and E; MICs of imipenem, 8 and 512 mg/L, respectively). MICs of tobramycin, rifampicin and colistin for both strains were 8, 8 and 0.5 mg/L, respectively. Results: In infections caused by strain D, lung bacterial counts (log10 cfu/g, mean ± s.d.) were: controls (10.86±0.25), imipenem (5.99±0.59, P < 0.05 versus controls), and colistin (10.43 ± 1.09); imipenem + tobramycin was the most active combination (5.46±0.62, P < 0.05 versus controls). In infections caused by strain E, results were: controls (10.82±0.33), rifampicin (5.62±0.26, P < 0.05 versus controls), colistin (8.38±1.22, P < 0.05 versus controls), and imipenem (11.01±0.2); rifampicin + imipenem (3.79±0.99) and rifampicin + tobramycin (3.96±0.30) were the most active combinations (P < 0.05); results with rifampicin + colistin (5.59±1.17) were similar to those with rifampicin alone. Conclusions: Our data indicate that imipenem can still be the best alternative for carbapenem-resistant A. baumannii infections with moderate levels of imipenem resistance, preferably combined with aminoglycosides. For strains highly resistant to imipenem, a combination of rifampicin with imipenem, tobramycin or colistin may be useful, if resistance to rifampicin is only moderate.
Revised September 23, 2004
Accepted September 28, 2004
Original article
Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model
2 Microbiology Department, Hospital de Bellvitge, University of Barcelona, C/Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
Abelardo Montero, E-mail: amontero{at}gencat.net
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Aoki, K. Tateda, Y. Kikuchi, S. Kimura, C. Miyazaki, Y. Ishii, Y. Tanabe, F. Gejyo, and K. Yamaguchi Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa J. Antimicrob. Chemother., March 1, 2009; 63(3): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Russo, J. M. Beanan, R. Olson, U. MacDonald, N. R. Luke, S. R. Gill, and A. A. Campagnari Rat Pneumonia and Soft-Tissue Infection Models for the Study of Acinetobacter baumannii Biology Infect. Immun., August 1, 2008; 76(8): 3577 - 3586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Landman, C. Georgescu, D. A. Martin, and J. Quale Polymyxins Revisited Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Peleg, H. Seifert, and D. L. Paterson Acinetobacter baumannii: Emergence of a Successful Pathogen Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo Global Challenge of Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3471 - 3484. [Full Text] [PDF]
|
|
|
|
|
|
T. Y. Tan, L. S. Y. Ng, E. Tan, and G. Huang In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates J. Antimicrob. Chemother., August 1, 2007; 60(2): 421 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Song, S. Y. Kee, I. S. Hwang, Y. B. Seo, H. W. Jeong, W. J. Kim, and H. J. Cheong In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii J. Antimicrob. Chemother., August 1, 2007; 60(2): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saballs, M. Pujol, F. Tubau, C. Pena, A. Montero, M. A. Dominguez, F. Gudiol, and J. Ariza Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections J. Antimicrob. Chemother., September 1, 2006; 58(3): 697 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Pachon-Ibanez, F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachon, and A. Pascual Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam J. Antimicrob. Chemother., September 1, 2006; 58(3): 689 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Wareham, D. C. Bean, C. M. Urban, and J. J. Rahal In Vitro Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., February 1, 2006; 50(2): 825 - 826. [Full Text] [PDF]
|
|